Go Back
Aclaris Therapeutics, Inc. reports $28.2 million Q1 loss
By USInMinutes - May 08, 2023, 08:57 AM ET
Last Updated - Jul 18, 2023, 03:34 PM EDT
The company generated $2.50 million in quarterly revenue
Aclaris Therapeutics, Inc. [ACRS] has reported fiscal Q1 loss of $28.20 million.
On a per-share basis, the DE based company said its diluted earnings are $0.42.
The Pharmaceutical Preparations firm posted revenue of $2.50 million in this period.
Also Read:
- Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update
- Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023
- Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory ...
- Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a ...
- Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference
NewsInMinutes is an offering of 10kInfo, Inc., bringing you news on the latest regulatory filings. You may subscribe to news alerts here.
Sponsored
Sponsored
Read More from Investing
Popular News
Latest News
